New PET tracer could reveal hidden breast cancer activity

NCT ID NCT03083288

Ongoing Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This early-phase trial tests a radioactive tracer called [18F]FluorThanatrace to see if it can measure PARP-1, a protein linked to breast cancer, using PET scans. Up to 30 people with known or suspected breast cancer will get a scan before surgery or therapy. The goal is to see if the tracer is safe and if it can help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]FluorThanatrace (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a better way to see breast cancer activity and tailor treatments without invasive biopsies.
What could go wrong: This is a very early phase 1 study with only 30 people. The tracer may not reliably show PARP-1 levels, and it is not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.